(SEM) Select Medical Holdings - Ratings and Ratios
Hospitals, Rehab, Outpatient, Therapy
SEM EPS (Earnings per Share)
SEM Revenue
Description: SEM Select Medical Holdings
Select Medical Holdings (NYSE:SEM) is a healthcare company operating in the Health Care Facilities sub-industry. The companys stock performance is influenced by its financial health, operational efficiency, and industry trends.
To evaluate SEMs financial health, key performance indicators (KPIs) such as revenue growth, operating margin, and return on equity (RoE) are crucial. With a RoE of 7.84%, the company generates a relatively modest return for its shareholders. Analyzing the income tax expense on a yearly basis can provide insights into the companys tax strategy and its impact on profitability.
The healthcare facilities sector is driven by demographic trends, such as an aging population, and government policies, including reimbursement rates for healthcare services. Key economic drivers for SEM include the demand for rehabilitation and long-term care services, as well as the overall healthcare spending in the US. The companys market capitalization of $1.46 billion and a forward P/E ratio of 11.45 suggest that investors have certain expectations regarding its future earnings growth.
To further assess SEMs stock, its essential to examine its price movement and trading activity. The stocks beta of 1.048 indicates that it is slightly more volatile than the overall market. Understanding the factors influencing its stock price, such as changes in healthcare policy or shifts in demand for its services, can help investors make informed decisions.
SEM Stock Overview
| Market Cap in USD | 1,652m |
| Sub-Industry | Health Care Facilities |
| IPO / Inception | 2009-09-25 |
SEM Stock Ratings
| Growth Rating | -25.7% |
| Fundamental | 42.6% |
| Dividend Rating | 26.1% |
| Return 12m vs S&P 500 | -34.9% |
| Analyst Rating | 4.50 of 5 |
SEM Dividends
| Dividend Yield 12m | 1.94% |
| Yield on Cost 5y | 2.25% |
| Annual Growth 5y | 10.02% |
| Payout Consistency | 45.6% |
| Payout Ratio | 15.5% |
SEM Growth Ratios
| Growth Correlation 3m | -18.1% |
| Growth Correlation 12m | -91.1% |
| Growth Correlation 5y | 17.1% |
| CAGR 5y | 3.66% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.08 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.24 |
| Sharpe Ratio 12m | -0.09 |
| Alpha | -40.88 |
| Beta | 1.075 |
| Volatility | 34.83% |
| Current Volume | 917k |
| Average Volume 20d | 1086.3k |
| Stop Loss | 13 (-3.1%) |
| Signal | 0.41 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (136.8m TTM) > 0 and > 6% of Revenue (6% = 346.0m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -0.49pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2.46% (prev 1.57%; Δ 0.89pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 413.2m > Net Income 136.8m (YES >=105%, WARN >=100%) |
| Net Debt (2.82b) to EBITDA (325.8m) ratio: 8.67 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.15 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (123.4m) change vs 12m ago -0.47% (target <= -2.0% for YES) |
| Gross Margin 11.46% (prev 12.84%; Δ -1.39pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 84.69% (prev 87.27%; Δ -2.58pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.12 (EBITDA TTM 325.8m / Interest Expense TTM 143.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.00
| (A) 0.02 = (Total Current Assets 1.08b - Total Current Liabilities 939.0m) / Total Assets 5.74b |
| (B) 0.14 = Retained Earnings (Balance) 804.7m / Total Assets 5.74b |
| (C) 0.02 = EBIT TTM 160.3m / Avg Total Assets 6.81b |
| (D) 0.21 = Book Value of Equity 799.7m / Total Liabilities 3.74b |
| Total Rating: 1.00 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 42.60
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield 4.07% = 2.03 |
| 3. FCF Margin 3.16% = 0.79 |
| 4. Debt/Equity 1.73 = 1.17 |
| 5. Debt/Ebitda 8.67 = -2.50 |
| 6. ROIC - WACC (= -0.79)% = -0.99 |
| 7. RoE 7.84% = 0.65 |
| 8. Rev. Trend -48.88% = -3.67 |
| 9. EPS Trend -27.85% = -1.39 |
What is the price of SEM shares?
Over the past week, the price has changed by +2.91%, over one month by +9.64%, over three months by -9.65% and over the past year by -25.34%.
Is Select Medical Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SEM is around 12.05 USD . This means that SEM is currently overvalued and has a potential downside of -10.21%.
Is SEM a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SEM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18 | 34.1% |
| Analysts Target Price | 18 | 34.1% |
| ValueRay Target Price | 12.9 | -3.8% |
Last update: 2025-10-13 02:04
SEM Fundamental Data Overview
P/E Trailing = 17.2987
P/E Forward = 11.2108
P/S = 0.313
P/B = 0.9632
P/EG = 1.37
Beta = 1.075
Revenue TTM = 5.77b USD
EBIT TTM = 160.3m USD
EBITDA TTM = 325.8m USD
Long Term Debt = 1.84b USD (from longTermDebt, last quarter)
Short Term Debt = 219.0m USD (from shortTermDebt, last quarter)
Debt = 2.88b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.82b USD (from netDebt column, last quarter)
Enterprise Value = 4.48b USD (1.65b + Debt 2.88b - CCE 52.3m)
Interest Coverage Ratio = 1.12 (Ebit TTM 160.3m / Interest Expense TTM 143.0m)
FCF Yield = 4.07% (FCF TTM 182.1m / Enterprise Value 4.48b)
FCF Margin = 3.16% (FCF TTM 182.1m / Revenue TTM 5.77b)
Net Margin = 2.37% (Net Income TTM 136.8m / Revenue TTM 5.77b)
Gross Margin = 11.46% ((Revenue TTM 5.77b - Cost of Revenue TTM 5.11b) / Revenue TTM)
Gross Margin QoQ = 11.60% (prev 13.34%)
Tobins Q-Ratio = 0.78 (Enterprise Value 4.48b / Total Assets 5.74b)
Interest Expense / Debt = 1.04% (Interest Expense 30.0m / Debt 2.88b)
Taxrate = 17.52% (12.3m / 70.2m)
NOPAT = 132.2m (EBIT 160.3m * (1 - 17.52%))
Current Ratio = 1.15 (Total Current Assets 1.08b / Total Current Liabilities 939.0m)
Debt / Equity = 1.73 (Debt 2.88b / totalStockholderEquity, last quarter 1.67b)
Debt / EBITDA = 8.67 (Net Debt 2.82b / EBITDA 325.8m)
Debt / FCF = 15.51 (Net Debt 2.82b / FCF TTM 182.1m)
Total Stockholder Equity = 1.75b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.38% (Net Income 136.8m / Total Assets 5.74b)
RoE = 7.84% (Net Income TTM 136.8m / Total Stockholder Equity 1.75b)
RoCE = 4.47% (EBIT 160.3m / Capital Employed (Equity 1.75b + L.T.Debt 1.84b))
RoIC = 3.40% (NOPAT 132.2m / Invested Capital 3.89b)
WACC = 4.19% (E(1.65b)/V(4.53b) * Re(9.98%) + D(2.88b)/V(4.53b) * Rd(1.04%) * (1-Tc(0.18)))
Discount Rate = 9.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.19%
[DCF Debug] Terminal Value 75.41% ; FCFE base≈224.6m ; Y1≈277.1m ; Y5≈472.8m
Fair Price DCF = 46.37 (DCF Value 5.75b / Shares Outstanding 124.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -27.85 | EPS CAGR: -47.52% | SUE: -1.02 | # QB: 0
Revenue Correlation: -48.88 | Revenue CAGR: -5.56% | SUE: -0.02 | # QB: 0
Additional Sources for SEM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle